Adaptive Biotechnologies Balance Sheet
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Adaptive Biotechnologies financial position
At the end of fiscal 2025, Adaptive Biotechnologies reported total assets of $512.7 million, down 4.9% from a year earlier against total liabilities of $287.7 million. Shareholders' equity stood at $218.8 million, or 42.7% of assets. The company held $70.5 million in cash and equivalents against $131.2 million of debt, a net debt position of $60.7 million.
The current ratio (current assets divided by current liabilities) was 3.34, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.60.
Summary generated from market data by MetaCap's automated system. Methodology
Adaptive Biotechnologies balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 70.50M | 47.92M | 65.06M | 90.03M | 139.06M | 123.44M | 96.58M | 55.03M | — |
| Short-Term Investments | 156.49M | 174.37M | 281.34M | 408.17M | 214.00M | 564.83M | 480.29M | 109.99M | — |
| Receivables | 50.37M | 41.73M | 37.97M | 40.06M | 17.41M | 10.05M | 12.68M | 4.81M | — |
| Inventory | 9.82M | 8.44M | 14.45M | 14.45M | 19.26M | 14.06M | 9.07M | 7.84M | — |
| Total Current Assets | 300.19M | 283.75M | 410.19M | 562.15M | 402.75M | 726.91M | 612.69M | 180.72M | — |
| Property, Plant & Equipment | 34.11M | 48.62M | 68.23M | 83.45M | 85.26M | 39.69M | 60.35M | 19.13M | — |
| Goodwill | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | — |
| Intangible Assets | 1.73M | 3.42M | 5.13M | 6.83M | 8.53M | 10.22M | 11.93M | 13.63M | — |
| Long-Term Investments | 13.23M | 33.66M | — | — | 217.15M | 118.53M | 105.44M | — | — |
| Total Assets | 512.74M | 539.38M | 661.13M | 856.62M | 923.34M | 1.12B | 912.30M | 332.69M | — |
| Accounts Payable | 6.47M | 7.26M | 7.72M | 8.08M | 3.31M | 3.24M | 4.45M | 1.79M | — |
| Short-Term Debt | 4.64M | 865.00K | — | — | — | — | — | — | — |
| Total Current Liabilities | 89.92M | 98.05M | 88.02M | 109.79M | 113.81M | 105.20M | 78.31M | 22.80M | — |
| Long-Term Debt | 126.57M | 132.41M | 130.66M | 125.36M | — | — | — | — | — |
| Total Liabilities | 287.74M | 336.89M | 352.86M | 392.52M | 319.24M | 373.15M | 341.26M | 29.94M | — |
| Shareholders' Equity | 218.79M | 202.71M | 308.40M | 464.17M | 603.99M | 743.27M | 571.04M | -258.11M | -224.62M |
| Retained Earnings | -1.36B | -1.30B | -1.14B | -919.08M | -718.89M | -511.61M | -365.48M | -295.91M | — |
| Total Debt | 131.21M | 133.28M | 130.66M | 125.36M | — | — | — | — | — |
| Net Cash (Debt) | 95.77M | 89.02M | 215.74M | 372.84M | 353.06M | 688.27M | 576.87M | 165.02M | — |
| Shares Outstanding | 153.78M | 147.77M | 145.08M | 143.11M | 141.39M | 137.65M | 125.24M | 12.84M | — |
This table shows 9 annual periods of Adaptive Biotechnologies's balance sheet, from FY 2025 back to FY 2017, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ADPT's reporting calendar. What is a balance sheet?